Minirin Melt (Desmopressin Acetate)

Desmopressin acetate, the active ingredient in Minirin Melt, is a vasopressin analog presented as a sublingual melt tablet for sublingual use. It treats central diabetes insipidus, nocturnal enuresis, primary nocturnal polyuria, and is used in hemophilia A and von Willebrand disease.

GNH USA supplies Minirin Melt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desmopressin acetate is employed in disorders where antidiuretic activity or coagulation factor elevation is required.

Central diabetes insipidus: reduces excessive urine output by enhancing water reabsorption in the kidneys. Nocturnal enuresis: decreases nighttime bedwetting by concentrating urine. Primary nocturnal polyuria: limits nocturnal urine volume through V2‑receptor activation. Hemophilia A: raises plasma factor VIII levels to improve clotting. Von Willebrand disease: increases von Willebrand factor, aiding haemostatic control.

Desmopressin acetate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or abdominal discomfort. - Nasal congestion or rhinorrhoea. - Facial flushing or warmth. - Mild hyponatraemia without symptoms.

Serious or Rare Side Effects: - Severe hyponatraemia leading to seizures or coma. - Water intoxication with rapid weight gain. - Allergic reactions such as rash, itching or angioedema. - Thrombotic events in patients with high factor VIII levels. - Hypertensive crisis when combined with vasopressin antagonists.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters. - Assess serum sodium: check baseline and periodically during treatment. - Monitor fluid balance: advise patients to limit excessive water intake. - Caution in renal impairment: adjust dose or increase monitoring frequency. - Use conservatively in the elderly: increased susceptibility to hyponatraemia. - Contraindicated in uncontrolled hyponatraemia or severe renal failure. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Desmopressin may interact with other medicines that affect water balance or coagulation.

Major Interactions (Avoid): - Concomitant use with vasopressin antagonists (e.g., conivaptan) can negate therapeutic effect. - Loop diuretics may exacerbate hyponatraemia risk. - Carbamazepine accelerates desmopressin clearance, reducing efficacy.

Moderate Interactions (Monitor Closely): - NSAIDs can impair renal prostaglandin synthesis, increasing hyponatraemia risk. - Antihypertensives may potentiate blood pressure changes when fluid shifts occur. - Estrogen‑containing therapies can enhance V2‑receptor response, requiring sodium monitoring.